Trade name(s)
Soriatane
Generic available
No
Drug class
Retinoid
Mechanism of action
Induction of cellular differentiation; anti-inflammatory; anti-proliferative
Dosage form
10mg, 25mg capsule
Dermatologic indications and dosage
See table
Acitretin. Dermatologic indications and dosage
Disease |
Adult dosage |
Child dosage |
|---|---|---|
Balanitis xerotica obliterans |
25–50mg PO daily as a single dose; after four weeks, 25–75mg PO daily |
10–25mg PO daily |
Berardinelli-Seip syndrome |
75mg PO daily |
10–25mg PO daily |
Darier disease |
25–50mg PO daily as a single dose; after four weeks, 25–75mg PO daily |
10–25mg PO daily |
Epidermolytic hyperkeratosis |
0.5–1mg per kg PO daily indefinitely |
0.5mg per kg PO daily indefinitely |
Erythrokeratodermia variabilis |
25–50mg PO daily indefinitely |
10–25mg PO daily |
Graft-versus-host disease |
1mg per kg PO daily |
10–25mg PO daily |
Hairy tongue |
25–50mg daily for up to 5 months |
10–25mg PO daily |
Harlequin ichthyosis |
1mg per kg PO daily |
1mg per kg PO daily indefinitely |
Hidradenitis suppurativa |
This is a preview of subscription content, log in via an institution to check access.
References
Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. Journal of the American Academy of Dermatology 41(3 Pt 2):S7–S12
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag
About this entry
Cite this entry
(2004). Acitretin. In: Levine, N., Levine, C.C. (eds) Dermatology Therapy. A to Z Essentials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29668-9_15
Download citation
DOI: https://doi.org/10.1007/3-540-29668-9_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-00864-4
Online ISBN: 978-3-540-29668-3
eBook Packages: Springer Book Archive